BioSpace23d
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and datopotamab deruxtecan (Dato-DXd), a TROP2 directed ADC, which are being jointly developed and commercialized globally ...
Targeted Oncology27d
No Improvement With Durvalumab vs Cetuximab in Advanced HNSCC
Treatment with durvalumab (Imfinzi) did not improve outcomes over cetuximab (Erbitux) when given to patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) undergoing ...
pharmaphorum2y
Enhertu gets breakthrough tag in HER2-low breast cancer
Enhertu is already approved as a third-line therapy for HER2-positive metastatic breast cancer and a second-line therapy for HER2-positive metastatic gastric cancer, and recent data from the ...
pharmaphorum4y
AZ/Daiichi Sankyo's Enhertu gets second US cancer indication
AstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has picked up a second indication, in patients who have stomach cancer and haven’t responded to Roche’s Herceptin (trastuzumab).